Cortechs.ai | Performance Evaluation for Multiple Sclerosis Identification Models Based on MRI  Imaging and Machine Learning

Performance Evaluation for Multiple Sclerosis Identification Models Based on MRI Imaging and Machine Learning

Cortechs.ai’ abstract titled “Determining Brain Age Using Machine Learning Combined With Automated Brain Segmentation and PET imaging In Normal, Alzheimer’s Disease and Mild Cognitive Impairment Subjects” was accepted by ACTRIMS

Lead author and Cortechs.ai Principal Scientist, Weidong Luo, presented our findings at the 2020 ACTRIMS meeting on Friday, February 28th.

Findings

BACKGROUND
Accurate and early diagnosis of Multiple Sclerosis (MS) is critical for patients to start treatments. In MS
patients, there is a high correlation between various atrophy and physical and cognitive impairments. With the recent
advances in image processing and machine learning methods, a better identification of MS patients using magnetic
resonance imaging (MRI) became achievable.
OBJECTIVE
To evaluate the performance of machine learning models for identifying MS subjects and to study feature
importance selected by models.
METHODS
463 MS (102m/361f, age:18-71yo) and 2315 normal subjects’ data (1080m/1235f, age:18-71yo) were used
in this study. T1-weighted MRI scans were processed by NeuroQuant 3.0 (Cortechs.ai Inc, San Diego, USA) to
generate brain volumetric information (including the volume of cerebral white matter (WM) hypo-intensities). Random
Forests algorithm was used for creating machine learning models. Brain structure volume normalized by Intracranial
Volume (ICV) were used as the input. One-third randomly selected data were used for testing while rest for training.
The performance of the models and the importance of the features based on the whole age range data and specific
age range data were evaluated.
RESULTS
For model one (all data), model area under the curve (AUC) is 0.95 and the precision is 93% and 98%;
sensitivity is 100% and 63% for normal and MS subjects respectively. Top five features are cerebral WM Hypo-
intensities, Thalamus and Cerebellar WM, Age and Isthmus Cingulate. For model two (age < 40 years), the model
AUC is 0.94 and the precision is 92% and 92% for normal and MS subjects while sensitivity is 98% and 76% for
normal and MS subjects respectively. Top three features are the same as the model one. Next two features are
cerebral WM and posterior Superior Temporal Sulcus. For model three (age >= 40 years), the AUC is 0.94 and the
precision is 94% and 96%, sensitivity is 100% and 57% for normal and MS subjects respectively. Top five features
Thalamus, Age, Cerebellar WM, Cerebral WM Hypo-intensities, Isthmus Cingulate.
CONCLUSION
Machine learning models showed high classification performance between normal and MS.
Furthermore, models constructed with data from different age ranges selected different key features thus enabled different precision and sensitivity performance for MS classification. This also suggests evolving effects of disease upon brain during progression. These models might be used as MS classifiers to assist clinicians in decision making.

 

Cortechs.ai | Performance Evaluation for Multiple Sclerosis Identification Models Based on MRI  Imaging and Machine Learning

More Resources

04/10/2026

OnQ Prostate Vendor Validation: From Research to Clinical Adoption

OnQ Prostate delivers consistent, reliable AI-powered prostate MRI insights across vendors, ensuring confident diagnosis and streamlined clinical workflows.

03/20/2026

Quantitative MRI, the McDonald Criteria, and the Future of Multiple Sclerosis Care

MRI is the foundation for diagnosing and monitoring multiple sclerosis (MS)

03/13/2026

Cortechs Cares: Community Impact and Volunteer Efforts in 2025

Cortechs Cares highlights how our team gave back in 2025 through community volunteer efforts, including an Alzheimer’s Walk and holiday toy drive.

03/11/2026

OnQ™ Prostate: Bringing Quantitative MRI to Prostate Imaging

Advancing prostate MRI with quantitative diffusion biomarkers. OnQ™ Prostate brings objective RSI-based insights to support data-driven cancer evaluation.

03/04/2026

Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies

NeuroQuant® Lesion Surveillance will be integrated into the Siemens Healthineers Digital Marketplace to advance quantitative brain imaging worldwide.

02/25/2026

Cortechs.ai Announces MFDS (KFDA) Approval of Global-Leading NeuroQuant® V5 Platform in South Korea

MFDS approves NeuroQuant® V5 in South Korea, expanding AI-driven volumetric neuroimaging and clinical decision support.
Scroll to Top